Monograph

S01LA05 - Aflibercept

Not porphyrinogenic

Rationale

Aflibercept is a fusion protein and is not metabolized by CYP enzymes. No potential porphyrinogenic effects are expected.

Chemical description

Aflibercept is a recombinant fusion protein.

Therapeutic characteristics

Aflibercept is indicated for the treatment of neovascular (wet) age-related macular degeneration. Visual impairment due to macular degeneration secondary to retinal vein occlusion, diabetic macular oedema or due to myopic choroidal neovascularization. Aflibercept is administered by intravitreal injections.

Hepatic exposure

A small amount of the drug enters the systemic circulation (Avary 2014).

Metabolism and pharmacokinetics

Free aflibercept binds to vascular endothelial growth factor to form a stable, inert complex. As with other large proteins, both free and bound aflibercept are expected to be cleared by proteolytic catabolism (SPC). The cytochrome P450 enzyme system is not involved in the metabolism of aflibercept (drugbank).

References

#	Citation details	PMID
*	Scientific articles
1.	systemic pharmacokinetics following intravitreal injections of ranibizumab, bevacizumab or aflibercept in patients with neovascular AMD. Avary RL et al. Br J Ophthalmology. 2014; 98 (12): 1636-1641.	24795335
*	Drug reference publications
2.	DrugBank. Aflibercept.
*	Summary of Product Characteristics
3.	The electronic Medicines Compendium (emc). Summary of Product Characteristics (SPC). Eylea.

Citation details

PMID

Scientific articles

systemic pharmacokinetics following intravitreal injections of ranibizumab, bevacizumab or aflibercept in patients with neovascular AMD.

Avary RL et al. Br J Ophthalmology. 2014; 98 (12): 1636-1641.

24795335

Drug reference publications

DrugBank. Aflibercept.

Summary of Product Characteristics

The electronic Medicines Compendium (emc). Summary of Product Characteristics (SPC). Eylea.

Similar drugs

Explore alternative drugs in similar therapeutic classes S01L / S01LA or go back.

Tradenames and packages

From some sources, we get a list of packages (United Kingdom, Ireland, Estonia). Other sources contain more or less "clean" versions of the trade name (Denmark, Finland, Iceland, Lithuania, Norway). What you see here is the raw data we get from each country, so there will appear to be duplicates. The bold names are the searchable terms. The gray names that follow are all mapped to the bolded term.

Note: The cleaning is done automatically by a proprietary algorithm, and it may produce errors. We strive to improve it continuously.

Netherlands

Eylea · Eylea 114,3 mg/ml oplossing voor injectie · Eylea 40 mg/ml oplossing voor injectie (in voorgevulde spuit of injectieflacon) · Yesafili · Yesafili 40 mg/ml oplossing voor injectie in een injectieflacon

Belgium

Eylea · Eylea 114.3 mg/ml sol. inj. i.vitr. flac. · Eylea 40 mg/ml sol. inj. i.vitr. flac. · Eylea 40 mg/ml sol. inj. i.vitr. ser. préremplie · Yesafili · Yesafili 40 mg/ml sol. inj. i.vitr. flac.

United Kingdom